Universal Ibogaine Inc (IBO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Universal Ibogaine Inc (IBO) has a cash flow conversion efficiency ratio of -0.405x as of April 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-110.36K ≈ $-79.84K USD) by net assets (CA$272.17K ≈ $196.89K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Universal Ibogaine Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Universal Ibogaine Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Universal Ibogaine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Universal Ibogaine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Universal Ibogaine Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Starbox Group Holdings Ltd. Ordinary Shares
NASDAQ:STBX
|
-0.001x |
|
Goldhills Holding Ltd
V:GHL
|
0.008x |
|
KB SPAC 6
KQ:208640
|
-0.119x |
|
Tongyang Inc
KO:001527
|
-0.008x |
|
Handal Resources Bhd
KLSE:7253
|
0.099x |
|
Distribution Finance Capital Holdings PLC
LSE:DFCH
|
0.088x |
|
Golden Prospect Precious Metals Ltd
LSE:GPM
|
-0.016x |
|
NANOSPHERE
F:3NS
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Universal Ibogaine Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Universal Ibogaine Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Universal Ibogaine Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-07-31 | CA$991.11K ≈ $716.95K |
CA$-838.61K ≈ $-606.64K |
-0.846x | -35.07% |
| 2023-07-31 | CA$1.75 Million ≈ $1.27 Million |
CA$-1.10 Million ≈ $-793.82K |
-0.626x | +43.00% |
| 2022-07-31 | CA$3.94 Million ≈ $2.85 Million |
CA$-4.33 Million ≈ $-3.13 Million |
-1.099x | -100.15% |
| 2021-07-31 | CA$-4.46K ≈ $-3.22K |
CA$-3.25 Million ≈ $-2.35 Million |
729.129x | +3068.20% |
| 2020-07-31 | CA$94.89K ≈ $68.64K |
CA$-2.33 Million ≈ $-1.69 Million |
-24.565x | -433.93% |
| 2019-07-31 | CA$197.12K ≈ $142.59K |
CA$-906.88K ≈ $-656.02K |
-4.601x | -324.00% |
| 2018-07-31 | CA$295.22K ≈ $213.56K |
CA$-320.34K ≈ $-231.73K |
-1.085x | -- |
About Universal Ibogaine Inc
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.